Masimo Outlines Growth Roadmap with 7%-10% Revenue CAGR, $8 EPS Target by 2028

Wednesday, Dec 3, 2025 4:12 pm ET1min read

Masimo hosted its 2025 Investor Day, updating its long-range plan through 2028 with financial targets including a 7-10% CAGR for revenue, a 30% operating margin, $8.00 adjusted EPS, and $1 billion cumulative operating cash flow from 2026-2028. The company also reaffirmed its 2025 guidance and emphasized its mission to deliver innovations that empower clinicians and transform patient care.

Masimo Outlines Growth Roadmap with 7%-10% Revenue CAGR, $8 EPS Target by 2028

Comments



Add a public comment...
No comments

No comments yet